HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Amir H Rezvani Selected Research

sazetidine-A

10/2013Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor β2-/- and α7-/- mice.
4/2013Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats.
5/2012Effects of sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats.
6/2011Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.
8/2010Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Amir H Rezvani Research Topics

Disease

11Alcoholism (Alcohol Abuse)
11/2016 - 03/2002
9Schizophrenia (Dementia Praecox)
01/2015 - 03/2003
9Cognitive Dysfunction
01/2015 - 02/2004
5Alzheimer Disease (Alzheimer's Disease)
10/2019 - 03/2003
5Tobacco Use Disorder (Nicotine Dependence)
10/2019 - 09/2003
5Acquired Immunodeficiency Syndrome (AIDS)
10/2019 - 03/2006
4Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
08/2011 - 03/2003
2Hypothermia
10/2013 - 05/2012
2Hallucinations (Hallucination)
02/2008 - 02/2004
1Chronic Pain
06/2020
1Opioid-Related Disorders (Opiate Addiction)
06/2020
1Birth Weight (Birth Weights)
07/2019
1Body Weight (Weight, Body)
09/2017
1Bipolar Disorder (Manic Depressive Psychosis)
04/2017
1Nervous System Diseases (Neurological Disorders)
01/2015
1Mental Disorders (Mental Disorder)
06/2011
1Ataxia (Dyssynergia)
04/2011
1Epilepsy (Aura)
08/2009
1Foodborne Diseases
06/2008
1Ciguatera Poisoning (Ciguatera)
06/2008
1Fever (Fevers)
04/2008
1Neurologic Manifestations (Neurological Manifestations)
04/2008
1Memory Disorders (Memory Loss)
01/2006
1Fetal Alcohol Spectrum Disorders
09/2005

Drug/Important Bio-Agent (IBA)

13NicotineFDA Link
08/2016 - 03/2003
8Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
09/2017 - 01/2006
6Antipsychotic Agents (Antipsychotics)IBA
05/2008 - 02/2004
5sazetidine-AIBA
10/2013 - 08/2010
4N-Methylaspartate (NMDA)IBA
10/2019 - 01/2006
3Glutamate Receptors (Glutamate Receptor)IBA
10/2019 - 01/2006
3Pharmaceutical PreparationsIBA
08/2012 - 02/2004
3Dizocilpine Maleate (Dizocilpine)IBA
05/2008 - 01/2006
3Clozapine (Clozaril)FDA LinkGeneric
05/2008 - 01/2006
3Ethanol (Ethyl Alcohol)IBA
05/2008 - 03/2002
23- (azetidin- 2- ylmethoxy)- 5- (phenylethynyl)pyridineIBA
09/2017 - 10/2013
2Neurotransmitter Agents (Neurotransmitter)IBA
08/2012 - 08/2009
2Methylphenidate (Ritalin)FDA LinkGeneric
08/2011 - 03/2009
2Naltrexone (ReVia)FDA LinkGeneric
08/2009 - 01/2007
2CiguatoxinsIBA
06/2008 - 04/2008
2SmokeIBA
02/2008 - 10/2007
2Cholinergic Agents (Cholinergics)IBA
03/2006 - 01/2006
1Opioid Analgesics (Opioids)IBA
06/2020
11- (3,4- dichlorophenyl)- 3- azabicyclo- (3.1.0)hexane hydrochlorideIBA
06/2020
1Memantine (Namenda)FDA Link
10/2019
1Excitatory Amino Acid AntagonistsIBA
10/2019
1Dronabinol (THC)FDA LinkGeneric
07/2019
1YL-2-203IBA
09/2017
1Biomarkers (Surrogate Marker)IBA
04/2017
1lorcaserinIBA
10/2014
1pyridineIBA
04/2013
1Cholinergic ReceptorsIBA
04/2013
1isproniclineIBA
10/2012
1S-2-O-carbamoyl-1-o-chlorophenyl-ethanolIBA
08/2009
1Acamprosate (Campral)FDA Link
08/2009
1Topiramate (Topamax)FDA LinkGeneric
08/2009
1Antidepressive Agents (Antidepressants)IBA
04/2009
1NeurotoxinsIBA
06/2008
1Voltage-Gated Sodium ChannelsIBA
06/2008
1Nicotinic AgonistsIBA
05/2008
1Hormones (Hormone)IBA
05/2008
1LigandsIBA
10/2007
1Anti-Anxiety Agents (Anxiolytics)IBA
01/2007
1JNJ-5234801IBA
01/2007
1Therapeutic UsesIBA
03/2006

Therapy/Procedure

6Therapeutics
11/2016 - 01/2006
2Self Administration (Administration, Self)
04/2011 - 09/2003
2Drug Therapy (Chemotherapy)
04/2009 - 06/2003
1Aftercare (After-Treatment)
10/2019
1Nicotine Replacement Therapy
01/2019
1Induced Hypothermia
10/2013